Clinical and Formulation Strategies for Targeted Peptide Drug Development: Q&A with Dr. Andrew Lewis
1 June 2025Rapid innovation in drug discovery, peptide engineering, and drug delivery is expanding the boundaries of peptide-based therapeutics.
Novel technologies and therapies are helping drug developers to overcome challenges associated with the development of injectable and oral peptide formulations, including rapid clearance, poor permeability, and instability in some drug product solutions, in plasma, and in the gastrointestinal (GI) tract.
Dr. Andrew Lewis, Chief Scientific Officer at Quotient Sciences, examined how chemistry, manufacturing, and controls (CMC) and clinical strategies for peptide drugs can be further improved, answering questions on the challenges and potential solutions associated with development of injectable and oral peptide drugs.
Download "Clinical and Formulation Strategies for Targeted Peptide Drug Development: Q&A with Dr. Andrew Lewis" to read the interview.